In our 2017 U.S. Transparency Report, we reported investing $7.9 billion in research and development, which is 88% more than its expenditure on marketing and sales. We maintained single-digit percentage increases in list prices, provided approximately $15 billion in discounts and rebates, and assisted around 610,000 commercially insured patients with out-of-pocket costs through the Janssen CarePath Savings Program.
Read the executive summary below, or view the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.